InMed Pharmaceuticals (INM) Non-Current Assets (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Non-Current Assets of $2.2 million for Q1 2026, down 21.75% year-over-year from $2.9 million in Q1 2025, and down 6.54% quarter-over-quarter from $2.4 million in Q4 2025.
InMed Pharmaceuticals (INM) Non-Current Assets (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Non-Current Assets history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 21.75% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $9.9 million (down 18.8% YoY), while the FY2025 annual figure was $2.7 million, down 13.42% from the prior year.
- Non-Current Assets for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $6.7 million in Q1 2022, with the low at $2.2 million in Q1 2026.
- The 5-year median for Non-Current Assets is $2.9 million (2022), against an average of $3.1 million.
- Peak annual rise in Non-Current Assets reached 365.3% in 2022, while the deepest fall reached 57.81% in 2022.
- InMed Pharmaceuticals' Non-Current Assets stood at $2.9 million in 2022, then rose by 18.73% to $3.4 million in 2023, then fell by 11.99% to $3.0 million in 2024, then declined by 20.76% to $2.4 million in 2025, then decreased by 6.54% to $2.2 million in 2026.
- Business Quant data shows INM's Non-Current Assets at $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.96 Bn |
| 10 | InMed Pharmaceuticals | 6.44 Mn | 1.20 Mn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.25 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 2.56 Mn |
| Jun 30, 2025 | 2.71 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 3.19 Mn |
| Jun 30, 2024 | 3.13 Mn |
| Mar 31, 2024 | 3.29 Mn |
| Dec 31, 2023 | 3.45 Mn |
| Sep 30, 2023 | 2.62 Mn |
| Jun 30, 2023 | 2.77 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Dec 31, 2022 | 2.90 Mn |
| Sep 30, 2022 | 3.04 Mn |
| Jun 30, 2022 | 3.19 Mn |
| Mar 31, 2022 | 6.74 Mn |
| Dec 31, 2021 | 6.88 Mn |
| Sep 30, 2021 | 1.35 Mn |
| Jun 30, 2021 | 1.40 Mn |